title: Gastrointestinal symptoms and association with medication use patterns, adherence, treatment satisfaction, quality of life, and resource use in osteoporosis: baseline results of the MUSIC-OS study.
abstract: CONCLUSIONS
  The Medication Use Patterns, Treatment Satisfaction, and Inadequate Control of Osteoporosis Study (MUSIC-OS) is a prospective, observational study of women with osteoporosis in Europe and Canada. At baseline, patients with gastrointestinal symptoms reported lower adherence to osteoporosis treatment, treatment satisfaction, and health-related quality of life, than those without gastrointestinal symptoms.
  
  
  BACKGROUND
  The aim of the study was to examine gastrointestinal (GI) symptoms and the association between GI symptoms and treatment adherence, treatment satisfaction, and health-related quality of life (HRQoL) among osteoporotic women in Europe and Canada.
  
  
  METHODS
  Baseline results are reported here for a prospective study which enrolled postmenopausal, osteoporotic women who were initiating (new users) or continuing (experienced users) osteoporosis treatment at study entry (baseline). A patient survey was administered at baseline and included the occurrence of GI symptoms during 6-month pre-enrolment, treatment adherence (adherence evaluation of osteoporosis (ADEOS), score 0-22), treatment satisfaction (Osteoporosis Treatment Satisfaction Questionnaire for Medications (OPSAT-Q), score 0-100) and HRQoL (EuroQol-5 dimension (EQ-5D) utility, score 0-1; OPAQ-SV, score 0-100). The association between GI symptoms and ADEOS (experienced users), OPSAT-Q (experienced users), and HRQoL (new and experienced users) was assessed by general linear models adjusted for patient characteristics.
  
  
  RESULTS
  A total of 2959 patients (2275 experienced and 684 new users) were included. Overall, 68.1% of patients experienced GI symptoms in the past 6 months. Compared with patients without GI symptoms, patients with GI symptoms had lower mean baseline scores on most measures. The mean adjusted differences were ADEOS, -0.43; OPSAT-Q, -5.68; EQ-5D, -0.04 (new users) and -0.06 (experienced users), all P < 0.01. GI symptoms were also associated with lower OPAQ-SV domain scores: physical function, -4.17 (experienced users); emotional status, -4.28 (new users) and -5.68 (experienced users); back pain, -5.82 (new users) and -11.33 (experienced users), all P < 0.01.
  
  
  CONCLUSIONS
  Patients with GI symptoms have lower treatment adherence and treatment satisfaction and worse HRQoL than patients without GI symptoms.
authors.affiliation: Merck and Co., Inc., Kenilworth, 2000 Galloping Hill Rd, Kenilworth, NJ, 07033, USA.
authors.forename: A
authors.initials: A
authors.lastname: Modi
authors.affiliation: Merck and Co., Inc., Kenilworth, 2000 Galloping Hill Rd, Kenilworth, NJ, 07033, USA.
authors.forename: S
authors.initials: S
authors.lastname: Sen
authors.affiliation: Division of Rheumatology, St. Joseph's Healthcare and McMaster University, Hamilton, ON, Canada.
authors.forename: J D
authors.initials: JD
authors.lastname: Adachi
authors.affiliation: University of Verona, Verona, Italy.
authors.forename: S
authors.initials: S
authors.lastname: Adami
authors.affiliation: University Hospital of Lille, Lille Cedex, France.
authors.forename: B
authors.initials: B
authors.lastname: Cortet
authors.affiliation: Bridge Medical Center, West Sussex, UK.
authors.forename: A L
authors.initials: AL
authors.lastname: Cooper
authors.affiliation: Maastricht University Medical Center, Maastricht, Netherlands.
authors.forename: P
authors.initials: P
authors.lastname: Geusens
authors.affiliation: University of Gothenburg, Göteborg, Sweden.
authors.forename: D
authors.initials: D
authors.lastname: Mellström
authors.affiliation: Merck and Co., Inc., Kenilworth, 2000 Galloping Hill Rd, Kenilworth, NJ, 07033, USA. jessica.weaver@merck.com.
authors.forename: J
authors.initials: J
authors.lastname: Weaver
authors.affiliation: Maastricht University Medical Center, Maastricht, Netherlands.|VieCuri Medical Center, Venlo, The Netherlands.
authors.forename: J P
authors.initials: JP
authors.lastname: van den Bergh
authors.affiliation: Merck and Co., Inc., Kenilworth, 2000 Galloping Hill Rd, Kenilworth, NJ, 07033, USA.
authors.forename: A M
authors.initials: AM
authors.lastname: Nguyen
authors.affiliation: Merck and Co., Inc., Kenilworth, 2000 Galloping Hill Rd, Kenilworth, NJ, 07033, USA.
authors.forename: S
authors.initials: S
authors.lastname: Sajjan
mesh_terms: D000368:Aged; D050071:Bone Density Conservation Agents / Q000009:adverse effects* / Q000627:therapeutic use; D002170:Canada / Q000453:epidemiology; D004164:Diphosphonates / Q000009:adverse effects / Q000627:therapeutic use; D005060:Europe / Q000453:epidemiology; D005260:Female; D005767:Gastrointestinal Diseases / Q000139:chemically induced* / Q000453:epidemiology / Q000523:psychology; D006295:Health Resources / Q000706:statistics & numerical data; D006801:Humans; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy* / Q000453:epidemiology / Q000523:psychology; D017060:Patient Satisfaction; D011446:Prospective Studies; D011594:Psychometrics; D011788:Quality of Life; D016903:Drug Monitoring
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates
keywords: Bisphosphonates; Gastrointestinal; Health-related quality of life; Osteoporosis; Postmenopausal; Treatment satisfaction